Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy

Fabio MazzolaniPrivate Practice, Milan, ItalyBackground: The purpose of this open-label study was to investigate the effect of a curcumin-phospholipid (lecithin, Meriva&reg;) formulation (Norflo&reg; tablet) on visual acuity and retinal thickness in patients with acute or chronic cen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Mazzolani F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/58d75bbf3e204cec8b374bbd77705fcf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:58d75bbf3e204cec8b374bbd77705fcf
record_format	dspace
spelling	oai:doaj.org-article:58d75bbf3e204cec8b374bbd77705fcf2021-12-02T02:48:20ZPilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy1177-54671177-5483https://doaj.org/article/58d75bbf3e204cec8b374bbd77705fcf2012-05-01T00:00:00Zhttp://www.dovepress.com/pilot-study-of-oral-administration-of-a-curcumin-phospholipid-formulat-a9981https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Fabio MazzolaniPrivate Practice, Milan, ItalyBackground: The purpose of this open-label study was to investigate the effect of a curcumin-phospholipid (lecithin, Meriva&reg;) formulation (Norflo&reg; tablet) on visual acuity and retinal thickness in patients with acute or chronic central serous chorioretinopathy.Methods: Visual acuity was assessed by ophthalmologic evaluation, and optical coherence tomography was used to measure retinal thickness. Norflo tablets were administered twice a day to patients affected by central serous chorioretinopathy. The study included 18 eyes from 12 patients who completed a 6-month follow-up period. Visual acuity before and after Norflo treatment was the primary endpoint. The secondary endpoints were neuroretinal or pigment epithelial detachment, as measured by optical coherence tomography.Results: After 6 months of therapy, 0% of eyes showed reduction in visual acuity, 39% showed stabilization, and 61% showed improvement. The improvement was statistically significant (P = 0.08). After 6 months of therapy, 78% of eyes showed reduction of neuroretinal or retinal pigment epithelium detachment, 11% showed stabilization, and 11% showed an increase.Conclusion: Our results, albeit preliminary, show that curcumin administered as Norflo tablets is efficacious for the management of central serous chorioretinopathy, a relapsing eye disease, and suggest that bioavailable curcumin is worth considering as a therapeutic agent for the management of inflammatory and degenerative eye conditions, including those that activate the retinal microglia.Keywords: curcumin, central serous chorioretinopathy, retinal pigment epithelium detachment, Norflo&reg;, Meriva&reg;Mazzolani FDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 801-806 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Mazzolani F Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
description	Fabio MazzolaniPrivate Practice, Milan, ItalyBackground: The purpose of this open-label study was to investigate the effect of a curcumin-phospholipid (lecithin, Meriva&reg;) formulation (Norflo&reg; tablet) on visual acuity and retinal thickness in patients with acute or chronic central serous chorioretinopathy.Methods: Visual acuity was assessed by ophthalmologic evaluation, and optical coherence tomography was used to measure retinal thickness. Norflo tablets were administered twice a day to patients affected by central serous chorioretinopathy. The study included 18 eyes from 12 patients who completed a 6-month follow-up period. Visual acuity before and after Norflo treatment was the primary endpoint. The secondary endpoints were neuroretinal or pigment epithelial detachment, as measured by optical coherence tomography.Results: After 6 months of therapy, 0% of eyes showed reduction in visual acuity, 39% showed stabilization, and 61% showed improvement. The improvement was statistically significant (P = 0.08). After 6 months of therapy, 78% of eyes showed reduction of neuroretinal or retinal pigment epithelium detachment, 11% showed stabilization, and 11% showed an increase.Conclusion: Our results, albeit preliminary, show that curcumin administered as Norflo tablets is efficacious for the management of central serous chorioretinopathy, a relapsing eye disease, and suggest that bioavailable curcumin is worth considering as a therapeutic agent for the management of inflammatory and degenerative eye conditions, including those that activate the retinal microglia.Keywords: curcumin, central serous chorioretinopathy, retinal pigment epithelium detachment, Norflo&reg;, Meriva&reg;
format	article
author	Mazzolani F
author_facet	Mazzolani F
author_sort	Mazzolani F
title	Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
title_short	Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
title_full	Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
title_fullStr	Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
title_full_unstemmed	Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
title_sort	pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/58d75bbf3e204cec8b374bbd77705fcf
work_keys_str_mv	AT mazzolanif pilotstudyoforaladministrationofacurcuminphospholipidformulationfortreatmentofcentralserouschorioretinopathy
_version_	1718402161874829312

Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy

Ejemplares similares